Zoetis Inc. (NYSE:ZTS) to Issue Quarterly Dividend of $0.53

Zoetis Inc. (NYSE:ZTS) declared a quarterly dividend on Wednesday, May 20th. Stockholders of record on Monday, July 20th will be paid a dividend of 0.53 per share on Tuesday, September 1st. This represents a c) dividend on an annualized basis and a dividend yield of 2.7%. The ex-dividend date of this dividend is Monday, July 20th.

Zoetis has increased its dividend payment by an average of 0.2%annually over the last three years and has increased its dividend every year for the last 14 years. Zoetis has a payout ratio of 31.0% meaning its dividend is sufficiently covered by earnings. Equities analysts expect Zoetis to earn $7.42 per share next year, which means the company should continue to be able to cover its $2.12 annual dividend with an expected future payout ratio of 28.6%.

Zoetis Stock Up 0.9%

Shares of Zoetis stock opened at $79.64 on Thursday. The firm’s 50 day moving average price is $109.69 and its 200-day moving average price is $119.37. The company has a quick ratio of 1.91, a current ratio of 3.15 and a debt-to-equity ratio of 2.80. Zoetis has a 52-week low of $72.38 and a 52-week high of $172.23. The company has a market cap of $33.39 billion, a P/E ratio of 13.21, a PEG ratio of 1.29 and a beta of 0.87.

Zoetis (NYSE:ZTS) last issued its quarterly earnings data on Thursday, May 7th. The company reported $1.53 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.60 by ($0.07). Zoetis had a return on equity of 66.85% and a net margin of 27.80%.The firm had revenue of $2.26 billion during the quarter, compared to analysts’ expectations of $2.30 billion. During the same period in the previous year, the firm earned $1.48 EPS. The firm’s quarterly revenue was up 2.9% on a year-over-year basis. Zoetis has set its FY 2026 guidance at 6.850-7.000 EPS. On average, sell-side analysts predict that Zoetis will post 6.88 EPS for the current fiscal year.

About Zoetis

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.